Cargando…
Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893545/ https://www.ncbi.nlm.nih.gov/pubmed/31731605 http://dx.doi.org/10.3390/nu11112774 |
_version_ | 1783476222247829504 |
---|---|
author | Vlot, Mariska C Boekel, Laura Kragt, Jolijn Killestein, Joep van Amerongen, Barbara M. de Jonge, Robert den Heijer, Martin Heijboer, Annemieke C. |
author_facet | Vlot, Mariska C Boekel, Laura Kragt, Jolijn Killestein, Joep van Amerongen, Barbara M. de Jonge, Robert den Heijer, Martin Heijboer, Annemieke C. |
author_sort | Vlot, Mariska C |
collection | PubMed |
description | Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)(2)D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)(2)D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)(2)D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)(2)D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study. |
format | Online Article Text |
id | pubmed-6893545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68935452019-12-23 Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations Vlot, Mariska C Boekel, Laura Kragt, Jolijn Killestein, Joep van Amerongen, Barbara M. de Jonge, Robert den Heijer, Martin Heijboer, Annemieke C. Nutrients Article Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)(2)D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)(2)D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)(2)D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)(2)D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study. MDPI 2019-11-15 /pmc/articles/PMC6893545/ /pubmed/31731605 http://dx.doi.org/10.3390/nu11112774 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vlot, Mariska C Boekel, Laura Kragt, Jolijn Killestein, Joep van Amerongen, Barbara M. de Jonge, Robert den Heijer, Martin Heijboer, Annemieke C. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title | Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title_full | Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title_fullStr | Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title_full_unstemmed | Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title_short | Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations |
title_sort | multiple sclerosis patients show lower bioavailable 25(oh)d and 1,25(oh)(2)d, but no difference in ratio of 25(oh)d/24,25(oh)(2)d and fgf23 concentrations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893545/ https://www.ncbi.nlm.nih.gov/pubmed/31731605 http://dx.doi.org/10.3390/nu11112774 |
work_keys_str_mv | AT vlotmariskac multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT boekellaura multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT kragtjolijn multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT killesteinjoep multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT vanamerongenbarbaram multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT dejongerobert multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT denheijermartin multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations AT heijboerannemiekec multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations |